[4] [4] KNACKSTEDT T, SAMIE F H. Sebaceous carcinoma: a review of the scientific literature[J]. Curr Treat Options Oncol, 2017, 18(8): 47. DOI: 10.1007/s11864-017-0490-0.

[5] [5] XU X L, LI B, SUN X L, et al. Eyelid neoplasms in the Beijing Tongren eye centre between 1997 and 2006[J]. Ophthalmic Surg Lasers Imaging, 2008, 39(5): 367-372. DOI: 10.3928/15428877-20080901-18.

[7] [7] OWEN J L, KIBBI N, WORLEY B, et al. Sebaceous carcinoma: evidence-based clinical practice guidelines[J]. Lancet Oncol, 2019, 20(12): e699-e714. DOI: 10.1016/S1470-2045(19)30673-4.

[8] [8] CHAO A N, SHIELDS C L, KREMA H, et al. Outcome of patients with periocular sebaceous gland carcinoma with and without conjunctival intraepithelial invasion[J]. Ophthalmology, 2001, 108(10): 1877-1883. DOI: 10.1016/s0161-6420(01)00719-9.

[9] [9] KALIKI S, AYYAR A, DAVE T V, et al. Sebaceous gland carcinoma of the eyelid: clinicopathological features and outcome in Asian indians[J]. Eye (Lond), 2015, 29(7): 958-963. DOI: 10.1038/eye.2015.79.

[10] [10] KALIKI S, GUPTA A, ALI M H, et al. Prognosis of eyelid sebaceous gland carcinoma based on the tumor (T) category of the American Joint Committee on Cancer (AJCC) classification[J]. Int Ophthalmol, 2016, 36(5): 681-690. DOI: 10.1007/s10792-016-0187-6.

[11] [11] SONG A, CARTER K D, SYED N A, et al. Sebaceous cell carcinoma of the ocular adnexa: clinical presentations, histopathology, and outcomes[J]. Ophthalmic Plast Reconstr Surg, 2008, 24(3): 194-200. DOI: 10.1097/IOP.0b013e31816d925f.

[12] [12] SHIELDS J A, DEMIRCI H, MARR B P, et al. Sebaceous carcinoma of the ocular region: a review[J]. Surv Ophthalmol, 2005, 50(2): 103-122. DOI: 10.1016/j.survophthal.2004.12.008.

[13] [13] PEREIRA P R, ODASHIRO A N, RODRIGUES-REYES A A, et al. Histopathological review of sebaceous carcinoma of the eyelid[J]. J Cutan Pathol, 2005, 32(7): 496-501. DOI: 10.1111/j.0303-6987.2005.00371.x.

[14] [14] SHIELDS J A, DEMIRCI H, MARR B P, et al. Sebaceous carcinoma of the eyelids: personal experience with 60 cases[J]. Ophthalmology, 2004, 111(12): 2151-2157. DOI: 10.1016/j.ophtha.2004.07.031.

[22] [22] OZDAL P C, CODRE F, CALLEJO S, et al. Accuracy of the clinical diagnosis of chalazion[J]. Eye (Lond), 2004, 18(2): 135-138. DOI: 10.1038/sj.eye.6700603.

[23] [23] KIVEL T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death[J]. Br J Ophthalmol, 2009, 93(9): 1129-1131. DOI: 10.1136/bjo.2008.150292.

[24] [24] ZHAO J Y, LI S F, SHI J T, et al. Clinical presentation and group classification of newly diagnosed intraocular retinoblastoma in China[J]. Br J Ophthalmol, 2011, 95(10): 1372-1375. DOI: 10.1136/bjo.2010.191130.

[25] [25] DIMARAS H, KIMANI K, DIMBA E A, et al. Retinoblastoma[J]. Lancet, 2012, 379(9824): 1436-1446. DOI: 10.1016/S0140-6736(11)61137-9.

[26] [26] DIMARAS H, CORSON T W, COBRINIK D, et al. Retinoblastoma[J]. Nat Rev Dis Primers, 2015, 1: 15021. DOI: 10.1038/nrdp.2015.21.

[27] [27] PARK S J, WOO S J, PARK K H. Incidence of retinoblastoma and survival rate of retinoblastoma patients in Korea using the Korean National Cancer Registry database (1993-2010)[J]. Invest Ophthalmol Vis Sci, 2014, 55(5): 2816-2821. DOI: 10.1167/iovs.14-14078.

[28] [28] JOKO-FRU W Y, PARKIN D M, BOROK M, et al. Survival from childhood cancers in eastern Africa: a population-based registry study[J]. Int J Cancer, 2018, 143(10): 2409-2415. DOI: 10.1002/ijc.31723.

[29] [29] LUO Y X, ZHOU C D, HE F L, et al. Contemporary update of retinoblastoma in China: three-decade changes in epidemiology, clinical features, treatments, and outcomes[J]. Am J Ophthalmol, 2022, 236: 193-203. DOI: 10.1016/j.ajo.2021.09.026.

[30] [30] RAJESHUNI N, WHITTEMORE A S, LUDWIG C A, et al. Racial, ethnic, and socioeconomic disparities in retinoblastoma enucleation: a population-based study, SEER 18 2000-2014[J]. Am J Ophthalmol, 2019, 207: 215-223. DOI: 10.1016/j.ajo.2019.04.015.

[31] [31] BERMAN E L, DONALDSON C E, GIBLIN M, et al. Outcomes in retinoblastoma, 1974-2005: the children's hospital, westmead[J]. Clin Exp Ophthalmol, 2007, 35(1): 5-12. DOI: 10.1111/j.1442-9071.2006.01386.x.

[32] [32] TOMAR A S, FINGER P T, GALLIE B, et al. High-risk pathologic features based on presenting findings in advanced intraocular retinoblastoma: a multicenter, international data-sharing American joint committee on cancer study[J]. Ophthalmology, 2022, 129(8): 923-932. DOI: 10.1016/j.ophtha.2022.04.006.

[33] [33] VEMPULURU V S, SHIELDS C L, BERRY J L, et al. Retinoblastoma outcomes based on the 8th edition American joint committee on cancer pathological classification in 1411 patients[J]. Ophthalmology, 2025, 132(3): 317-326. DOI: 10.1016/j.ophtha.2024.08.037.

[36] [36] VEMPULURU V S, TANNA V, LUTHRA A, et al. Eyelid/periocular sebaceous gland carcinoma in 500 eyes: analysis based on 8th edition American joint cancer committee classification[J]. Am J Ophthalmol, 2025, 269: 49-59. DOI: 10.1016/j.ajo.2024.07.036.

[37] [37] KWON M, LEE J S, LEE C, et al. Prognostic factors for relapse and survival among patients with ocular adnexal lymphoma: validation of the eighth edition of the American Joint Committee on Cancer (AJCC) TNM classification[J]. Br J Ophthalmol, 2021, 105(2): 279-284. DOI: 10.1136/bjophthalmol-2020-315875.